Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
Growth from the medical device company's smaller divisions offers hope that the firm can turn around its sales slump.
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Investors have gotten their money's worth out of Boston Scientific's (BSX +0.00%) stock lately. Shares of the medical device maker have surged by more than 30% in the past six months alone, rising higher despite the company's troubles. Sales have fallen into a slump at Boston Scientific, led lower by the company's cardiac rhythm management, or CRM, business, which produces everything from pacemakers to implantable defibrillators. This is an industry on the decline -- Medtronic (MDT +0.00%), a leader in the medical device field, has seen its own CRM sales slump in recent quarters, while Boston Sci rival St. Jude Medical (STJ +0.00%) has similarly had its top line hammered by its CRM division's falling revenue.
Boston Scientific is more than just a cardiovascular device maker, however -- and its smaller, growing divisions invite hope for the company's future despite the slump in its core business. In this video, Motley Fool contributor Dan Carroll and health care analyst Max Macaluso discuss one of Boston Scientific's hot growing businesses and why investors should pay attention to the company's upcoming earnings report to see whether it's making the right moves to turn around its lagging sales.
Alert: Top Cash Back Card Now Offers 0% Intro APR Until Nearly 2027
Enjoy 0% intro APR on purchases and balance transfers for 15 months—plus up to 5% cash back in popular categories.
Motley Fool Returns
Market-beating stocks from our flagship service.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 2025-08-29 12:21:46.613853.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
